戈利木单抗治疗中重度溃疡性结肠炎的临床研究进展

被引：8

作者：

冯静

机构：

[1] 武汉大学人民医院药学部

来源：

现代药物与临床 | 2019年 / 34卷 / 03期

关键词：

戈利木单抗; 溃疡性结肠炎; 疗效; 安全性;

D O I：

暂无

中图分类号：

R574.62 [结肠疾病];

学科分类号：

100201 [内科学];

摘要：

戈利木单抗作为一种新型的抗肿瘤坏死因子(TNF)-α制剂,已在国外开展了经典的诱导缓解研究试验和维持缓解研究试验。临床试验已证实其对中重度溃疡性结肠炎的治疗有较好效果,具有起效快、临床缓解率和黏膜愈合率高以及不良反应少等优点。主要对戈利木单抗已开展的经典临床研究试验、疗效和安全性以及存在的问题和解决办法的研究进展进行综述,以期为临床安全合理使用戈利木单抗提供参考。

引用

页码：872 / 876

页数：5

共 16 条

[1]

Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study [J].

Maia Bosca-Watts, Marta ;

Cortes, Xavier ;

Iborra, Marisa ;

Maria Huguet, Jose ;

Sempere, Laura ;

Garcia, Gloria ;

Gil, Rafa ;

Garcia, MariFe ;

Munoz, Marga ;

Almela, Pedro ;

Maroto, Nuria ;

Maria Paredes, Jose .

WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (47) :10432-10439

[2]

Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study) [J].

Hibi, Toshifumi ;

Imai, Yuya ;

Senoo, Asako ;

Ohta, Kentaro ;

Ukyo, Yoshifumi .

JOURNAL OF GASTROENTEROLOGY, 2017, 52 (10) :1101-1111

[3]

Golimumab for moderate to severe ulcerative colitis [J].

Strik, Anne S. ;

Berends, Sophie E. ;

Mathot, Ron A. ;

D'Haens, Geert R. ;

Lowenberg, Mark .

EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2017, 11 (05) :401-406

[4]

Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease.[J].Mitrev;Leong.Expert Opinion on Drug Safety.2017, 3

[5]

Letter: effectiveness of golimumab to induce remission in outpatient ulcerative colitis in Italy [J].

Tursi, A. ;

Della Valle, N. ;

Penna, A. ;

Pranzo, G. ;

Ricciardelli, C. ;

Picchio, M. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 43 (05) :657-658

[6]

Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis [J].

Rutgeerts, P. ;

Feagan, B. G. ;

Marano, C. W. ;

Padgett, L. ;

Strauss, R. ;

Johanns, J. ;

Adedokun, O. J. ;

Guzzo, C. ;

Zhang, H. ;

Colombel, J-F. ;

Reinisch, W. ;

Gibson, P. R. ;

Sandborn, W. J. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (05) :504-514

[7]

OP009 Long-term safety and efficacy of golimumab in patients with moderately to severely active ulcerative colitis: Results from the PURSUIT-SC Maintenance study extension.[J].W. Reinisch;P. Gibson;W.J. Sandborn;B.G. Feagan;C. Marano;R. Strauss;J. Johanns;H. Zhang;L. Padgett;J.-F. Colombel;J. Collins;P. Rutgeerts.Journal of Crohn's and Colitis.2014,

[8]

Optimizing anti-TNF treatments in inflammatory bowel disease [J].